Web16 de jul. de 2024 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for patients with anaemia due to chronic kidney … Web15 de jul. de 2024 · SAN FRANCISCO, July 15, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration …
Arcus Biosciences - Arcus Biosciences Presents Updated Data …
Web12 de mai. de 2024 · HIF Global urges you to carefully review and consider the cautionary statements made in this press release and cautions you not to place undue reliance on forward-looking statements, which speak ... WebJesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of chronic kidney disease a new oral treatment option; GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for … northern new york attractions
HIF Global Secures US$ 260 Million in Equity Investments
Web2 de dez. de 2024 · Press Release 02 December 2024 Siemens Energy and Porsche Munich / Stuttgart. Siemens Energy and Porsche, with partners, ... Siemens Energy is a co-developer of the “Haru Oni” project (also known as HIF project), and is serving as a systems integrator to cover the entire value chain ... Web6 de dez. de 2024 · HIF Global urges you to carefully review and consider the cautionary statements made in this press release and cautions you not to place undue reliance on forward-looking statements, which speak ... WebGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl … northern new york city